anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lipocalin-2 (LCN2) is essential for the regulation of neuroinflammation and cellular uptake of iron. This study aimed to evaluate plasma LCN2 levels and explore their correlation with clinical and neuroimaging features in Parkinson's disease (PD) patients. Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma LCN2 levels in 120 subjects. Evaluation of motor symptoms and nonmotor symptoms in PD patients was assessed by the associated scales. Voxel-based morphometry (VBM) was used to evaluate brain volume alterations, and quantitative susceptibility mapping (QSM) was used to quantitatively analyze brain iron deposition in 46 PD patients. Plasma LCN2 levels were significantly higher in PD patients than those in healthy controls. LCN2 levels were negatively correlated with Montreal Cognitive Assessment (MoCA) scores, total brain gray matter volume (GMV), and GMV/total intracranial volume (TIV) ratio, but positively correlated with Hamilton Anxiety Rating Scale (HAMD) scores and mean QSM values of the bilateral substantial nigra (SN). Receiver operating characteristic (ROC) curves confirmed that plasma LCN2 levels had good predictive accuracy for PD. The results suggest that plasma LCN2 levels have potential as a biomarker for the diagnosis of PD. LCN2 may be a therapeutic target for neuroinflammation and brain iron deposition.
This study is a multicentered, controlled, randomized, open trial with blinded assessment of the primary outcome measure (Prospective Open Blinding Endpoint PROBE study). Randomization will be stratified by sex assigned at birth and the investigating center. The main analysis will be intention-to-treat and multiple imputation methods will be used to handle missing data. Once inclusion criteria are checked by the child psychiatrist (selection visit), and the pediatric endocrinologist (inclusion visit), the adolescent will be included in the study with an initial evaluation (T0) by a trained psychologist : primary measure (CGAS) and secondary psycho-affectif criteria. Then, the subject will randomized by the pediatric endocrinologist (via an IT platform) and, if included in the experimental arm will be given the cross sex hormonal treatment corresponding.Main objective: To evaluate, in adolescents with gender dysphoria (GD), having or not benefited from prior pubertal suppression, the effectiveness of cross sex hormonal treatment with estrogens or testosterone initiated at 14 years of age on the overall functioning of the teenager at 16 years old. Primary outcome measure: Children's Global Assessment Scale (CGAS) score at age 16. Secondary measures : Evaluate the effectiveness of cross sex hormonal treatment started at 14 years old vs. 16 years old on the overall functioning of the adolescent at 18 years old, - the safety (side effects) of hormonal treatment started at the age of 14, - and the relevance of hormonal treatment started at 14 years old on other measures assessed at 16 and 18 years old (gender identity, depression, anxiety, emotional, behavioral disorders and other comorbidities, objective and subjective quality of life, body image, height, waist/hip ratio, bone mineral density, BMI). Adolescents in both groups will be re-evaluated at 16 years +/- 6 months (T1). At the end of this evaluation, patients in the control group will begin their hormonal treatment. Adolescents will benefit from a final evaluation at 18 years +/- 6 months, (T2), the same criteria as at T0 and T1 will be collected.
Serum sodium between 135 - 145 milliequivalent/L. Mannitol 100 ml every 4 hours for the first three days; 80 ml every 4 hours the fourth day; 60 ml every 4 hours the fifth day and 40 ml every 4 hours the sixth day and then stopping. The mannitol protocol will be interrupted at any moment if serum sodium is below 135, the systolic blood pressure is below 90 mmHg or the patient has signs of hypovolemia. In this case, 2 ml/kg of 3% sodium chloride every 4 hours will be used until the target of serum sodium is achieved and both, normovolemic state and blood pressure are restored. In addition, the mannitol protocol will be suspended when serum osmolality is above 320.
Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator.
Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 1-3 million cells per kilogram body weight . This is a one time treatment at the time of Stage II Glenn surgery .
BACKGROUND/AIM: Most clear cell renal cell carcinomas (ccRCCs) have a dysfunctional von Hippel-Lindau tumor suppressor protein (VHL). Hypoxia-inducible factors 1 and 2 alpha (HIF1α and HIF2α) accumulate in ccRCC with dysfunctional VHL and up-regulate the vascular endothelial growth factor (VEGF) pathway and tumor angiogenesis. Recently, pimitespib (PIM), a potent ATP-competitive inhibitor of heat shock protein 90 (HSP90), was developed. PIM down-regulates the expression of HIF, a key protein in ccRCC progression, with anti-angiogenic effects. This study aimed to examine the effectiveness of PIM in ccRCC and the underlying mechanisms.
MATERIALS AND METHODS: The efficacy and mechanism of PIM against ccRCCs was evaluated using ccRCC cell lines.
RESULTS: PIM inhibited the VEGFR pathway by down-regulating VEGFR 2, phosphorylated VEGFR 2, and protein levels in downstream signaling pathways. The growth of ccRCC cell lines was inhibited by PIM. Furthermore, PIM inhibits HIF1α, HIF2α, and VEGF expression, suggesting that PIM may suppress angiogenesis in addition to the VEGFR pathway.
CONCLUSION: PIM provides a novel approach for treating ccRCC and holds promise for future clinical strategies. Further in vivo and clinical research is required to elucidate the detailed relationship between the effects of PIM and ccRCC.
PURPOSE:To obtain a pearlescent shampoo composition effective for imparting hair with excellent hair-conditioning property and resistant to the separation of pearlescent component by adding a specific amount of a mixture of two ester compounds to a specific amount of a dimethylsilicone emulsion. CONSTITUTION:The objective composition is produced by compounding 0.01-1wt.% (in terms of dimethylsilicone) of an emulsion of a dimethylsilicone of formula I (R1 and R2 are methyl or H; n is 4,000-9,000) and 0.1-3 wt.% of a mixture of an ester compound of formula II (R1 is 11-17C alkyl) and an ester compound of formula III. The compound of formula I is e.g. Toshiba Silicone TSE-200, the compound of formula II is e.g. ethylene glycol distearate and the compound of formula III is e.g. ethylene glycol myristate.
The invention discloses a 2-(alpha-hydroxy amyl) benzamide derivate as well as a preparation method, a preparation and an application of the deviate. The structural formula of the 2-(alpha-hydroxy amyl) benzamide derivate is shown in the specification, wherein R1 is a link group; and R2 is a functional group containing carboxyl. The preparation method comprises the following steps: performing ring-opening reaction for butylphthalide serving as the raw material to obtain an intermediate product a; and performing condensation reaction for the intermediate product a and a carboxyl-containing compound. The preparation is prepared by adding pharmaceutically acceptable auxiliary materials and can be in a form of powder, a tablet, a capsule, granules, a dropping pill, a honeyed pill, a lyophilized agent or injection. The application includes the application in preparation of medicines for preventing/treating cardio-cerebral ischemia, cardio-cerebral arterial occlusion, parkinson disease and senile dementia. According to the preparation method, opened-loop butylphthalide and ozagrel or clopidogrel and other medicines with platelet aggregation resisting effects are linked through an amido bond so as to be synthesized into a butylphthalide prodrug with a plurality of pharmacologic effects.
The group that will be consuming probiotics (LT-002 (Lactobacillus reuteri ATG-F4)) for 12 weeks. The subjects will take a daily intake of 4 x 10\^10 colony forming unit (CFU) of LT-002.
Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
A soluble CTLA4 mutant molecule which binds CD86 has an amino acid sequence shown in specification, wherein the amino acid at position 29 designated Xaa is alanine or tyrosine and the amino acid at position 106 designated Yaa is glutamic acid, asparagine, aspartic acid, glutamine, isoleucine, leucine, or threonine. A soluble mutant CTLA4Ig fusion protein reactive with the CD86 antigen has a first amino acid sequence consisting of the extracellular domain of CTLA4 mutant as shown in specification and a second amino acid sequence consisting of the hinge, CH2 and CH3 regions of human immunoglobulin Cyl. An isolated nucleic acid molecule and its equivalent cDNA encoding the amino acid sequence corresponding to the soluble mutant CTLA4 or soluble mutant CTLA4Ig fusion protein as defined above are disclosed. Also disclosed are a plasmid comprising the cDNA as defined above and a host vector system comprising the plasmid. The soluble CTLA4 mutant molecule as defined above is useful for regulating functional CTLA4 positive T-cell interactions with CD80 and CD86 positive cells such as for treating immune system diseases mediated by T cell interactions with CD80 and CD86 positive cells. The soluble CTLA4 mutant molecule as defined above and a ligand reactive with IL-4 are used in the manufacture of a medicament for inhibiting graft versus host disease in a subject.
This study describes patient perceptions related to device attributes, which are of importance in describing overall patient perception. A range of potential device benefits (e.g. ease of use, convenience, confidence, presence or absence of fear, side effects related to administration) is captured using a questionnaire based on the outputs of patient interviews.

The study aims to characterize patient attributes that will indicate when one device may result in greater patient satisfaction than another. Patient attributes are composed of patient characteristics (e.g. age, sex, self efficacy, expectations of treatment, perception of their illness) and RA characteristics (e.g. disease severity, disease duration, prior treatment, functional impairment).
AIM: Growth differentiation factor 15 (GDF15) is a stress response cytokine that has been proposed as a relevant metabolic hormone. Descriptive studies have shown that plasma GDF15 levels are regulated by short term changes in nutritional status, such as fasting, or in obesity. However, few data exist regarding how GDF15 levels are regulated in peripheral tissues. The aim of the present work was to study the variations on gastric levels of GDF15 and its precursor under different physiological conditions, such as short-term changes in nutritional status or overfeeding achieved by HFD. Moreover, we also address the sex- and age-dependent alterations in GDF15 physiology.
METHODS: The levels of gastric and plasma GDF15 and its precursor were measured in lean and obese mice, rats and humans by western blot, RT-PCR, ELISA, immunohistochemistry and by an in vitro organ culture system.
RESULTS: Our results show a robust regulation of gastric GDF15 production by fasting in rodents. In obesity an increase in GDF15 secretion from the stomach is reflected with an increase in circulating levels of GDF15 in rats and humans. Moreover, gastric GDF15 levels increase with age in both rats and humans. Finally, gastric GDF15 levels display sexual dimorphism, which could explain the difference in circulating GFD15 levels between males and females, observed in both humans and rodents.
CONCLUSIONS: Our results provide clear evidence that gastric GDF15 is a critical contributor of circulating GDF15 levels and can explain some of the metabolic effects induced by GDF15.
The present invention relates to a novel DCDGF protein which is a member of a novel family of growth factors of which the prototype is called Insect-Derived Growth Factor (IDGF). In particular, isolated nucleic acid molecules are provided encoding the human DCDGF protein. DCDGF polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DCDGF activity. Also provided are diagnostic methods for diagnosing DiGeorge Syndrome and, particularly, immune system-related disorders. and therapeutic methods for treating immune system-related disorders.
INTRODUCTION: Posterior instrumented stabilization is a commonly done surgery in spinal tuberculosis. This study aims to evaluate the clinical, radiological, and neurological outcomes of posterior instrumented stabilization and transpedicular decompression in thoracic and lumbar spinal tuberculosis.
METHODS: A descriptive cross-sectional study was conducted for one and a half years with at least six months of follow-up in a tertiary care center. The study was approved by the Institutional Review Committee (Reference number: 119 (6-11-5) 2/075-076). Total sampling was done and the study included patients over 18 years of age with spinal tuberculosis of the thoracic or lumbar regions. These patients underwent posterior instrumented stabilization and transpedicular decompression at the tertiary care center. The age, site of involvement, Visual Analog Scale score for back pain, neurological status as per Frankel Neurology grading, and local kyphotic angle in X-ray were recorded. The median, interquartile range and percentage were calculated. The data was entered in Microsoft Excel 2016 and analysis was done using Epi Info software version 7.2.
RESULTS: Thoracic level was most commonly involved in 14 (46.68%) cases. The median back pain as assessed by the Visual Analogue Scale score improved from 8 to 2 at the 6-month follow-up. There was improvement in the neurological grading of all cases and there was no loss of correction in the local kyphotic angle till the final follow-up. The median age of cases was 48 years (interquartile range: 28-62.50).
CONCLUSIONS: Posterior instrumented stabilization and transpedicular decompression in adult patients with thoracic or lumbar spinal tuberculosis achieves improvements in clinical, radiological, and neurological outcomes.
PURPOSE:To obtain a beautifying and whitening cosmetic having suppressing effects on melanogenesis, effects on rapid lightening of the pigmentation color on the skin and suppressing effects on inflammation with ultraviolet rays without any skin irritation. CONSTITUTION:A beautifying and whitening cosmetic is obtained by blending (A) a melilotus extract with (B) a deproteinized blood serum. The amounts of the ingredients based on the beautifying and whitening cosmetic are 0.01-5.0wt.% ingredient (A) and 0.001-3.0wt.% ingredient (B). This beatifying and whitening cosmetic is excellent in beautifying and whitening effects and suppressing effects on inflammation. Furthermore, the ingredient (A) is extracted from a stem, a leaf, a root or the whole herb of Melilotus officinalis (L.) Lam. belonging to the subfamily Caesalpinioideae of the family Leguminosae and contains melilotoside, melilotic acid, coumarin, their related substances, etc. The ingredient (B) can be produced by adding acetone to blood of a calf, etc., free of cellulose, then adding a 1:1 mixture of acetone with ether, centrifuging the mixture, subsequently drying the resultant substance, adding distilled water and trypsin, fermenting the obtained mixture at pH 8 and 37 deg.C, then dialyzing the fermentation liquor with cellophane and concentrating the dialyzate.
PURPOSE:To prepare stable and fine water suspension of fat-soluble material by coating the fat-soluble material which insoluble or hardly soluble in water but soluble in an org. solvent by using fatty particle membrane in the milk of mammals and then suspending the particles in water. CONSTITUTION:A fat-soluble material which is insoluble or hardly soluble in water but soluble in an org. solvent is coated with fatty particle membrane in the milk of mammals and then suspended in water. Namely, the fat-soluble material and fatty particle membrane in the milk of mammals are emulsified by a physical method to prepare fine water suspension of fat-soluble material. More concretely, after bioactive peptide is dissolved or suspended in water, neutral fat and fatty particle membrane in the milk of mammal are added thereinto and emulsified by a physical method to prepare the water suspension of the bioactive peptide.
Apply high-flow nasal oxygenation during apnea with open mouth after adequate preoxygenation. Resume bag-mask ventilation when pulse oximetry drops to 92% or pre-set apnea time has expired.
Modakafusp alfa TBD, infusion, IV, once every 4 weeks (Q4W) on Day 1 of each 28-day treatment cycle until treatment discontinuation. The starting dose will be decided by the investigators and sponsor representatives based on all available clinical information.
Stabilizing formulation (A) for compositions that contain immunoglobulin G (IgG) comprises a sugar alcohol (I), glycine (II) and a nonionic detergent (III). It effectively stabilizes both liquid and lyophilized IgG compositions. An independent claim is also included for an IgG-containing composition, in liquid form or as lyophilizate, that contains (A). ACTIVITY : Immunosuppressive. No biological data given. MECHANISM OF ACTION : None given.
The liver is the most important organ for biological transformation in the body and is crucial for maintaining the body's vital activities. Liver injury is a serious pathological condition that is commonly found in many liver diseases. It has a high incidence rate, is difficult to cure, and is prone to recurrence. Liver injury can cause serious harm to the body, ranging from mild to severe fatty liver disease. If the condition continues to worsen, it can lead to liver fibrosis and cirrhosis, ultimately resulting in liver failure or liver cancer, which can seriously endanger human life and health. Therefore, establishing an rodent model that mimics the pathogenesis and severity of clinical liver injury is of great significance for better understanding the pathogenesis of liver injury patients and developing more effective clinical treatment methods. The author of this article summarizes common chemical liver injury models, immune liver injury models, alcoholic liver injury models, drug-induced liver injury models, and systematically elaborates on the modeling methods, mechanisms of action, pathways of action, and advantages or disadvantages of each type of model. The aim of this study is to establish reliable rodent models for researchers to use in exploring anti-liver injury and hepatoprotective drugs. By creating more accurate theoretical frameworks, we hope to provide new insights into the treatment of clinical liver injury diseases.
Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m\^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m\^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
Compounds of formula (I), wherein Ar, n, R1, R2, R3 and R4 are defined in the specification, as well as pharmaceutically acceptable prodrug derivatives and pharmaceutically acceptable salts thereof, exhibit valuable pharmaceutical properties, especially as inhibitors of TNF-alpha activity and of matrix-degrading metalloproteinases. Therefore, they can be used in the treatment of a large spectrum of diseases, e.g. as antiinflammatory agents for the treatment of e.g. osteoarthritis, rheumatoid arthritis, or as antitumor agents e.g. for the treatment and prevention of tumor growth, tumor metastasis, tumor invasion or progession. They are prepared in a manner known per se.
Subcutaneous injections with birch pollen allergoid were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
Children and adolescent participants with anxiety disorder receive cognitive behavioral therapy (CBT) for a 12-week period. In the final eight weeks of the trial, the subjects complete the Active Attention Bias Modification Training (ABMT), computer-based attention bias modification training aimed at re-training attentional biases before a CBT session: Part 1. modified dot-probe task, where a target is always presented at the previous location of the neutral and not the simultaneously presented threatening stimulus. Part 2. visual search, where the targets are always presented distally of threatening distractors.
<P>PROBLEM TO BE SOLVED: To provide a wound protective agent, capable of facilitating manufacture, lowering the cost and presenting convenience for use, preventing adhesion to the skin tissue, and continuing the sterilizing effect for long time, and a manufacturing method therefor.  <P>SOLUTION: A pad part 25 is provided with a water-contained gel layer 16 in which a sterilizing disinfectant is dissolved. The water-contained gel layer 16 is held by a gel support 18, and the gel support 18 is held by a pressure sensitive support material 12. The water-contained gel layer 16 contains chemical such as ethyl alcohol or water soluble sterilizing disinfectant. The water- contained gel layer 16 is composed of water soluble high polymer material such as high polymer polysaccharide dissolved by heating or solidified by cooling.  <P>COPYRIGHT: (C)2003,JPO
Embodiments are directed toward facilitating securely and efficiently providing medical-test results. Some embodiments enable secure and efficient mass testing by eliminating the requirement that patients provide personally identifying information after collection of their first testing specimen. The system enables delivering test results to such patients without the patients providing personally identifying information with specimens to be tested. The first time that a patient requests a medical test on a specimen, values representative of biometric characteristic thereof are recorded with personal information for the patient. Some embodiments facilitate looking up the patient's personal information by using values representative of biometrics obtained from the patient's subsequent specimens to be medically tested. Some embodiments facilitate security by storing personal information and biometric identifiers in separate data stores and linking records in those data stores by way of an identifier that does not identify the patient.